Alembic has firmed up a joint venture to tap into emerging opportunities in China amid evolving regulations there, and believes the market holds significant promise despite rising price pressures.
Alembic Pharmaceuticals Ltd., which reported a sturdy set of numbers for the fiscal fourth quarter ended March 2019, has outlined a broad vision for its China joint venture, though management commentary appeared cautiously optimistic, underscoring it is still early days and that China's regulations are still evolving.
“It's a massive market where the government is doing a lot of interesting stuff in terms of access to healthcare,” Pranav Amin, Alembic’s managing
As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.
A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.
Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.
